Even though the cost of Tivicay is 25 times higher in Trinidad and Tobago compared to other countries in the region, GSK says that its pricing is based on several factors such as country income classification.
The AIDS Healthcare Foundation has pointed fingers at “greedy” GSK over the pricing of its human immunodeficiency virus drug Tivicay (dolutegravir) in Trinidad and Tobago, stating that the drug “costs 25 times more than available biosimilar generics in neighboring Caribbean countries.”
The global non-profit organization has urged the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay, which would allow
As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
